Skip to main content
. 2016 Apr;67(4):576–584. doi: 10.1053/j.ajkd.2015.09.020

Figure 1.

Figure 1

Effect of allocation to simvastatin plus ezetimibe treatment on all major atherosclerotic events in SHARP (Study of Heart and Renal Protection). 183% of participants in this category with chronic kidney disease (CKD) stage 3b (estimated glomerular filtration rate of 30-<45 mL/min/1.73 m2). Abbreviations: CI, confidence interval; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol.